نتایج جستجو برای: abvd

تعداد نتایج: 396  

Journal: :Hematological Oncology 2021

PET CT adapted treatment for first line Hodgkin Lymphoma has been widely studied in the last decades. Long-term follow-up is important to judge both efficacy and safety of this approach. Patients Methods: We analyzed updated data on all patients (pts.) treated within LH-05 GATLA trial. Newly diagnosed pts. with HL Stages I-IV were included. All received 3 ABVD evaluated a PET-CT (PET-CT+3). Pts...

2015
AGOSTINO CHIARAVALLOTI MARCO PAGANI MARIA CANTONETTI BARBARA DI PIETRO MARIO TAVOLOZZA LAURA TRAVASCIO DANIELE DI BIAGIO ROBERTA DANIELI ORAZIO SCHILLACI

The aim of the present study was to investigate brain glucose metabolism in patients with Hodgkin disease (HD) after diagnosis and during chemotherapy treatment. Following the administration of first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy, 74 HD patients underwent 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography ...

Journal: :Blood 2012
Anas Younes Yasuhiro Oki Peter McLaughlin Amanda R Copeland Andre Goy Barbara Pro Lei Feng Ying Yuan Hubert H Chuang Homer A Macapinlac Fredrick Hagemeister Jorge Romaguera Felipe Samaniego Michelle A Fanale Bouthaina Shbib Dabaja Maria A Rodriguez Nam Dang Larry W Kwak Sattva S Neelapu Luis E Fayad

In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treated with rituximab 375 mg/m(2) weekly for 6 weeks and standard ABVD for 6 cycles. The primary outco...

Journal: :Oncology 2012
Chris R Kelsey Anne W Beaven Louis F Diehl Leonard R Prosnitz

Multiple randomized studies have demonstrated that chemotherapy, most commonly ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine), followed by consolidation radiation therapy is the most effective treatment program for early-stage Hodgkin lymphoma. With a combined-modality approach, the great majority of patients are cured of their disease. It is also apparent that both chemot...

Journal: :Blood 2012
Stephen J Proctor Jennifer Wilkinson Gail Jones Gillian C Watson Helen H Lucraft Tryfonia Mainou-Fowler Dominic Culligan Michael J Galloway Katrina M Wood Richard J Q McNally Peter W James John R Goodlad

The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n = 175). The central element was a phase 2 study of VEPEMB chemotherapy (n = 103, median age 73 years) incorporating comorbidity assessment. A total of 72 other patients were treated off-study but registered prospectively and treated con...

2015
Hussein Sh

Purpose of the study: was to estimate the value of early assessment of response in pediatric Hodgkin lymphoma (PHL) patients using FDG-PET/CT. Methods: prospective analysis of 195 patients presented in Children’s Cancer Hospital, Egypt (CCHE) with pathologically proven untreated PHL, they underwent F-fluorodeoxyglucose positron emission tomography (F-18 FDG PET/CT) early after 2 cycles of chemo...

2018
Hongying Wu Liyan Wei Lumei Hao Xuemei Li Lei Wang Chenglu Yuan

Hodgkin lymphoma (HL) is a lymphoproliferative disease arising in the lymphoid tissue, which is characterized by Reed–Sternberg cells. Adenocarcinoma is the most frequent pathological type of stomach cancer. Improved survival in HL patients leads to the development of secondary malignancies. However, synchronous occurrence of these 2 malignancies is extremely rare. Here, we present a 45-year-ol...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید